ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Bacillus-based probiotics ameliorate bleomycin-induced pulmonary fibrosis in rats: coupling intestinal barrier reinforcement to the modulation of M2 macrophage polarization/TGF-β/p38MAPK and inflammasome-driven pyroptosis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis (PF) is a chronic, progressive lung disorder with an 87.5% mortality rate recorded in aged patients. Emerging evidence bridges gut dysbiosis to PF pathogenesis. The consumption of a Bacillus-based probiotic exhibited immunomodulatory and anti-inflammatory effects by alleviating gut dysbiosis and restoring gut microbiome composition, positioning it as a promising therapeutic strategy for gut-organ axis disorders. The present study investigated the therapeutic effects of Bacillus-based probiotics in a rat model of PF by targeting the gut-lung axis. Rats were randomly assigned to five groups: Group I (the normal control group) and Group II received a single intratracheal instillation of bleomycin (BLM) (5 mg/kg). All treated groups received BLM and commenced treatment fourteen days later. Group III: received B. clausii. Group IV: received B. coagulans. Group V: received a combination of both strains. In vitro and in vivo analyses showed that the probiotic strains exhibited gut survivability, colonization associated with restoration of intestinal barrier integrity, and an SCFA profile. The dual therapy exerted a notable immunomodulatory effect by suppressing pulmonary M2 macrophage polarization (CD206 and Arg1), inhibiting the TGF-β/p38MAPK-JNK/NF-κB signaling cascade, mitigating inflammatory and fibrotic responses, and diminishing NLRP3/Caspase-1/IL-1β/GSDMD-N-mediated pyroptosis, thereby disrupting the vicious cycle of inflammation and fibrogenesis. Interplay with the Nrf2 axis activates antioxidant defense. This study resolves this knowledge gap by investigating the therapeutic potential of Bacillus-based probiotics to alleviate PF by modulating the gut-lung axis, offering an innovative platform for the treatment of PF that extends beyond current Lactobacillus-focused research.
Indexed as
Identifiers
42873256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.